CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

galunisertib

Small moleculeexperimental

Galunisertib (LY2157299) is a small molecular experimental cancer drug previously in development by Eli Lilly. It is a TGF-b inhibitor. Development of galunisertib by Eli Lilly was discontinued in January 2020. — Wikipedia

Clinical trial activity

26 trials · 22 clinical orgs · 0 marketing orgs

Phase 1
18
Phase 2
12
Phase 3
1
Phase 4
0

Earliest trial started Dec 1, 2005 (NCT01682187)

Timeline

2000s

  1. Jan 1, 2005

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1
Mol. weight
369.43 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4h-pyrrolo(1,2-b)pyrazol-3-yl)quinoline-6-carboxylic acid amide
  • galunisertib
  • galunisertib
  • galunisertib
  • galunisertib
  • galunisertib
  • ly2157299
  • ly2157299
  • ly2157299
  • ly 2157299
  • ly-2157299
  • ly-2157299
  • ly-2157299

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05700656Phase 1/Phase 2 (Phase 2)Apr 30, 2023Netherlands Cancer Institute, University of Amsterdam
NCT04605562Phase 2Jun 30, 2022Sun Yat-Sen University
NCT03470350Phase 1/Phase 2 (Phase 2)Aug 24, 2018Agendia, Catalan Institute of Health, Eli Lilly, European Organisation for Research and Treatment of Cancer, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milano, INCLIVA, Katholieke Universiteit Leuven, Netherlands Cancer Institute, Universidad Autonoma de Barcelona, University of Campania Luigi Vanvitelli, University of Turin, University of Valencia
NCT03206177Phase 1Aug 20, 2017Eli Lilly, University of Oklahoma
NCT02906397Phase 1Mar 30, 2017University of Pennsylvania
NCT03081377Phase 1Mar 29, 2017University of Pennsylvania
NCT02981342Phase 2Jan 1, 2017Eli Lilly
NCT02734160Phase 1Jun 1, 2016AstraZeneca, Eli Lilly
NCT02688712Phase 2Jun 1, 2016Eli Lilly, Providence Health & Services
NCT02452008Phase 2Apr 1, 2016Johns Hopkins University
NCT02752919Phase 1Apr 1, 2016Eli Lilly
NCT02672475Phase 1Mar 1, 2016National Cancer Institute (NCI), Vanderbilt University
NCT02423343Phase 1/Phase 2 (Phase 2)Oct 1, 2015Bristol-Myers Squibb, Eli Lilly
NCT02304419Phase 1May 1, 2015Eli Lilly
NCT02240433Phase 1Nov 1, 2014Eli Lilly
NCT02178358Phase 2Aug 1, 2014Eli Lilly
NCT02154646Phase 1May 1, 2014Eli Lilly
NCT02008318Phase 2/Phase 3 (Phase 3)Mar 1, 2014Eli Lilly
NCT01965808Phase 1Oct 1, 2013Eli Lilly
NCT01746004Phase 1Jan 1, 2013Eli Lilly
Showing 20 of 26 trials
Page 1 / 2

Organizations

Research & Development (22)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Eli LillyFor profit201732005
Netherlands Cancer InstituteAcademic/Hospital2212018
University of PennsylvaniaAcademic/Hospital2212017
AgendiaFor profit1012018
AstraZenecaFor profit1012016
Bristol-Myers SquibbFor profit1012015
Catalan Institute of HealthGovernment1012018
European Organisation for Research and Treatment of CancerAcademic/Hospital1012018
Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, MilanoAcademic/Hospital1012018
INCLIVAAcademic/Hospital1012018
Johns Hopkins UniversityAcademic/Hospital1112016
Katholieke Universiteit LeuvenAcademic/Hospital1012018
National Cancer Institute (NCI)Government1012016
Providence Health & ServicesAcademic/Hospital1112016
Sun Yat-Sen UniversityAcademic/Hospital1112022
Universidad Autonoma de BarcelonaAcademic/Hospital1012018
University of AmsterdamAcademic/Hospital1012023
University of Campania Luigi VanvitelliAcademic/Hospital1012018
University of OklahomaAcademic/Hospital1112017
University of TurinAcademic/Hospital1012018
22 organizations
Page 1 / 2